A Jehovah's Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions

Therapy for acute leukemia in Jehovah's Witnesses patients is very challenging because of their refusal to accept blood transfusions, a fundamental supportive therapy for this disease. These patients are often denied treatment for fear of treatment-related death. We present the first Jehovah�...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yumi, Kawashima, Akihito, Kashiwagi, Eri, Ogata, Kiyoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202254/
https://www.ncbi.nlm.nih.gov/pubmed/25371835
http://dx.doi.org/10.1155/2014/141260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202254/
https://www.ncbi.nlm.nih.gov/pubmed/25371835
http://dx.doi.org/10.1155/2014/141260

Ejemplares similares